Testing of CMV-specific interferon-γ release in whole blood is not predictive for the development of CMV viremia in kidney and stem cell transplant patients

K. Haug, B. Lange, D. Huzly, M. Vavra, M. Geyer, H. Bertz, P. Pisarski, J. Finke, W. V. Kern & D. Wagner
Introduction: Cytomegalovirus (CMV) reactivation remains a significant cause of morbidity both in kidney (KTR) and hematopoietic stem cell transplantation recipients (HCTR). A diminished CMV-specific T-cell response might be a better predictor of CMV reactivation compared to plasma viremia. We hypothesized[for full text, please go to the a.m. URL]